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Over the past forty years, liver transplantation (OLT)
has evolved from an experimental, surgical procedure
with a low likelihood of success to a universally accepted
multi-disciplinary endeavor for the treatment of both
acute liver failure and end-stage liver disease. In 2008,
the expectation of 1-year post-transplant survival is
greater than 85% for most indications, and indeed, the
majority of clinical challenges have been addressed [1–
3]. In that context, the expectation for most liver graft
recipients is one of achieving long-term survival in con-
junction with signiﬁcantly improved quality of life [4–8].
For younger patients, the expectation of contributing
to society means considerably more than merely return-
ing to the workforce or achieving speciﬁc goals. For
younger patients, who have undergone successful
OLT, the expectation in 2008 is one of a full and normal
life, including the ability to have children, and enjoy-
ment of normal sexual relations. In this, the 11th Forum
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National Transplant Pregnancy Registry, NTPR.combination of topics reﬂecting the full tapestry of
issues pertaining to sexual health and function, contra-
ception and pregnancy in the OLT recipient. Addition-
ally, we examine the rare indications for
transplantation in patients who develop liver failure as
a consequence of pregnancy.2. Pregnancy-related liver disease: is there ever an
indication for liver transplantation? (Markus Selzner)
Alteration in aspects of liver function is normal dur-
ing pregnancy. Severe liver dysfunction is rare, but when
it occurs, it can do so in a catastrophic fashion for both
mother and infant. Liver disease in pregnancy can be
considered in three separate categories. First, liver dys-
function speciﬁc to the pregnant state, i.e. conditions
occurring only in the setting of pregnancy. Second, man-
agement of the pre-existing disorders that may be pro-
voked by the pregnant state, i.e. pre-existing liver
disease that must cope with the extra physiological
demands of pregnancy. Finally, liver disease coincident
with pregnancy, i.e. apparent concurrent liver condi-
tions occurring in a pregnant woman that do not typi-
cally aﬀect the pregnancy. In the context of liver
transplantation, it is this ﬁrst category that is most
pertinent.
Liver failure in its broadest sense, occurring in the
context of the pregnant state is rare, and is most often
caused by acute fatty liver of pregnancy (AFLP),
eclampsia-related liver disease, or the haemolysis, ele-
vated liver enzymes, low platelet count (HELLP) syn-
drome. Indeed, the distinction between eclampsia-
related liver disease in pregnancy, HELLP syndromePublished by Elsevier B.V. All rights reserved.
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cult to distinguish one from another. These speciﬁc con-
ditions typically occur in the third trimester of
pregnancy but may present at any time during preg-
nancy or even in the early post-partum period [9]. In
considering a diﬀerential diagnosis in patients who
may present with liver failure, it is important to reﬂect
on conditions outwith those that occur only in the preg-
nant state. These are summarized in Table 1.
AFLP and HELLP syndromes are both infrequent
with AFLP reported as occurring in 1/7000–15,000
pregnancies. First described in 1934 by Sheehan et al.
as a yellow atrophy of the liver, the condition has been
widely described and signiﬁcant advances in the patho-
genesis of the condition reported [10–13]. Histological
ﬁndings are those of severe microvesicular steatosis in
association with minimal necrosis.
Acute fatty liver of pregnancy is regarded as one of
the family of diseases characterised by a mitochondrial
cytopathy, which also includes conditions such as Reye’s
Syndrome, drug-related liver disease and other genetic
defects in mitochondrial function. Ultimately, these con-
ditions are characterised by vomiting, hypoglycaemia,
lactic acidosis, hyperammonaemia and microvesicular
fat in organs. Acidosis occurs as a result in defective
energy supply within the mitochondria during oxidative
phosphorylation. Hypoglycaemia in these disorders may
relate to failure of mitochondrial tricarboxylic acid cycle
enzymes [11–13].
The understanding of the pathogenesis of the condi-
tion has been greatly enhanced by the description of full
term infants born to mothers with AFLP in whom hyp-
oglycaemia, hepatic encephalopathy and steatosis devel-
oped. The infants were found to have a defect in fattyTable 1
Liver dysfunction in pregnancy in patients without pre-existing liver
disease
Liver disease speciﬁc to pregnancy
Acute fatty liver of pregnancy
Hypertension-associated liver disease of pregnancy
Pre-eclampsia and eclampsia
Hepatic infarction, hematoma and rupture
HELLP syndrome
Liver disease coincident with pregnancy
Acute viral hepatitis Hepatitis A–E
Herpes simplex hepatitis
Drug toxicity
Acetaminophen toxicity
Budd-Chiari syndrome
Liver transplant recipients
Consideration should be given in diﬀerential diagnosis to each of these
conditions. For patients with liver disease speciﬁc to pregnancy, it is
pertinent to consider that it is frequently clinically diﬃcult to diﬀer-
entiate between HELLP syndrome AFLP and eclampsia-related liver
disease. In all such instances, early delivery and intensive supportive
care may abrogate the need for liver transplant.acid oxidation, and speciﬁcally were deﬁcient in long-
chain 3-hydroxyacyl coenzyme A dehydrogenase
(LCHAD)[13]. In a seminal investigation, this pattern
was noted in 11 women whose pregnancies were compli-
cated by acute fatty liver with features of HELLP syn-
drome. Six babies from this series were found to have
LCHAD deﬁciency[13]. Heterozygosity for LCHAD in
the mother appears to be responsible at least in part
for the development of disease in the infant. The molec-
ular basis has been identiﬁed as the substitution of gua-
nosine to cytosine in the alpha-subunit that catalyses the
last three steps of beta oxidation. Consistent with these
ﬁndings is the fact that in murine models, pregnancy
decreases fatty oxidation with the eﬀect mediated by
estrogens and progesterones.
Patients with AFLP present in the third trimester at a
mean gestational age 34 weeks with non-speciﬁc symp-
toms, such as vomiting, malaise, fever, and abdominal
pain [13]. In later stages, patients develop jaundice,
coagulopathy, hypoglycaemia, and encephalopathy.
Serum transaminases rarely exceed 1000 IU/L, and usu-
ally ranges from 300 to 500 IU/L [14]. Disseminated
intravascular coagulation (DIC) may occur in up to
70% of cases. In severe cases, the clinical course may
be complicated by hepatic necrosis and liver rupture.
The diﬀerential diagnosis includes acute viral hepatitis
and HELLP syndrome. Ultrasound imaging and viral
serological assessment are required in all cases. Liver
biopsy is not mandatory but may be necessary if the
diagnosis is clinically unclear, the liver function tests
do not normalise after delivery or, the diagnosis of
ALFP is required as an indication for delivery [15].
The therapy of choice is rapid delivery, usually by cae-
sarian section.
In the past, AFLP was considered to be universally
fatal, but aggressive optimization in the peri-delivery
period, has improved the prognosis with both maternal
and foetal mortality rates ranging from 0% to 20%
reported in the literature [16]. Although AFLP may pro-
gress to acute liver failure (ALF), liver transplantation is
rarely indicated/required since the condition is typically
reversible following delivery. Liver transplantation
should be considered in cases with severe disseminated
intravascular coagulation (DIC), rupture of the liver,
or severe encephalopathy. Where present, the cardinal
management paradigm is emergency delivery by caesar-
ian section, with aggressive supportive care. OLT is per-
formed only in the context of failure to recover liver
function.
In the European Liver Transplantation Registry
(ELTR) database (www.eltr.org) 75,530 liver transplan-
tations have been recorded since 1968. OLT has been
performed in only six instances for AFLP during this
time, (Rene´ Adam, personal communication) demon-
strating that transplantation is rarely required, and is
only indicated in exceptional cases of advanced disease.
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ure during pregnancy is the HELLP syndrome, which
was ﬁrst described by Weinstein et al. in 1982 and usu-
ally occurs towards the end of pregnancy in young pri-
magravidae [17]. The pathogenesis of HELLP
syndrome is unclear but an imbalance of prostacyclin
and thromboxane has been suggested [18,19]. Patients
with HELLP syndrome typically have evidence of pre-
eclampsia as well as thrombocytopenia. The HELLP
syndrome aﬀects about 6/1000 pregnancies and mani-
fests most frequently in the 34th gestational week. How-
ever, 10–30% of cases occur within the ﬁrst six days
post-partum [9]. The most common presenting symptom
is abdominal pain but as many as 40% of all cases may
be asymptomatic. The clinical course can be compli-
cated by renal failure, pulmonary edema, cerebral hem-
orrhage, and seizures. Serum aspartate aminotransferase
(AST) is usually elevated to a mean level of 250 IU/L,
but levels in excess of 7000 IU/L have been reported.
The condition may not meet criteria for ALF since the
prothrombin time is typically normal, except in its most
extreme form when DIC may exist. The severity of the
histological changes are not usually reﬂected by the lab-
oratory abnormalities, and biopsy of the liver is not
mandatory for diagnosis. The most important diﬀeren-
tial diagnoses are acute viral hepatitis, idiopathic throm-
bocytopaenia purpura, and AFLP. The treatment of
choice is early delivery. Once delivered, the infants have
no liver involvement and an appropriate outcome for
the gestational age may be anticipated. In most
instances there are no long-term sequelae for the mother
although the condition may recur in subsequent
pregnancies.
In 2–3% of the cases, HELLP syndrome can lead to a
variety of hepatic complications such as subcapsular
liver hemorrhage and subsequent hepatic rupture,
resulting in the death of either mother and/or foetus
[20]. Such patients present in shock, with abdominal
hemorrhage and require rapid laparotomy and surgical
management with packing of the liver. In addition,
HELLP syndrome can also lead to hepatic infarction
with signiﬁcant aminotransferase elevation. This is typ-
ically identiﬁed on axial imaging such as computed
tomography and frequently is accompanied by coagu-
lopathy and progressive encephalopathy, i.e. ALF.
While the overall mortality of the HELLP syndrome is
2–3%, the presence of hepatic complications increases
the maternal mortality to 50%, and in such cases, trans-
plant should be considered [21].
Only case reports and one small series about liver
transplantation for HELLP syndrome have been
reported. Zarrinpar et al. reported the largest series of
liver transplantation for HELLP syndrome [22]. A
review of 3090 adult liver transplant operations per-
formed at a single center revealed that eight patients
were transplanted for this indication [22]. The most fre-quent clinical manifestations in this group were enceph-
alopathy, renal failure, DIC, and respiratory failure. A
mean model for end-stage liver disease (MELD) score
of 40 at the time of OLT typiﬁes the severity of liver dis-
ease. In the report, four patients developed primary
non-function after transplantation resulting in one
death. After three successful re-transplantations in the
remaining patients, a 5-year patient survival of 88%
was reported. In the European Liver Transplant Regis-
try (www.eltr.org) only four of 75,530 liver transplanta-
tions were performed for liver involvement of HELLP
syndrome (Rene´ Adam personal communication), sug-
gesting that only selected cases with severe liver involve-
ment require transplantation.3. When does sexual function become normal after liver
transplantation? (Eric M. Yoshida)
Despite the great wealth of accumulated post-trans-
plant medical knowledge, sexuality or ‘‘sexual health”
remains largely unexplored post-liver transplantation
out-with questions and variables on generic quality of
life instruments.
3.1. Challenges in exploring and investigating sexual
health post-liver transplantation
There are many possible reasons why sexual health
has been poorly studied following OLT, despite its
importance to recipients and their partners. In the highly
specialized arena of the post-transplant clinic, physi-
cians, surgeons and allied health care professionals
may not feel comfortable dealing with questions regard-
ing sexual health. Many healthcare providers feel that it
is outside of their area of expertise and that they have
too little to oﬀer patients. Similarly, primary care physi-
cians who are less familiar with liver transplantation
often assume that post-transplant patients have more
life-threatening transplant-related issues to contend
with, and that a return to ‘‘normal” life after transplan-
tation is unlikely.
From an academic perspective, the topic itself is,
admittedly, a diﬃcult one to study. Sexual attitudes
and practices amongst patient populations are heteroge-
neous and vary from community to community and
temporally from generational cohort to generational
cohort. Even within individual patients, sexuality
changes with time. The subject matter itself is also con-
troversial, just as it is in the greater society.
Similar to contemporary society, some patients may
perceive any enquiry or investigation of post-transplant
sexuality to be ‘‘oﬀensive” and a factor that will nega-
tively aﬀect participation rates in clinical studies. This
in turn leads to questions regarding the internal validity
of studies, since participation and non-participation
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the generalisability of study ﬁndings from one country
to another and from one time-point to another becomes
problematic.
3.2. Sexual health pre-liver transplantation
End-stage liver disease is well recognised as altering
the normal physiology of the hypothalamic–pituitary–
gonadal axis, which in turn can aﬀect sexual function
in these patients. In male patients, cirrhosis is associated
with decreased levels of serum testosterone [23–27],
inappropriately low levels of the pituitary gonadal stim-
ulating hormones, lutenizing hormone (LH) [23–25,27]
and follicular stimulating hormone (FSH) [23,25,26,28]
and possibly blunting of pituitary responses to gonado-
trophic-releasing hormones [29] resulting in a hypogo-
nadal state. In addition, serum levels of oestrogens
[24,28] and prolactin [26,27] are elevated in cirrhotic
men that may further contribute to sexual dysfunction.
Although these endocrinologic eﬀects aﬀect patients
with cirrhosis of any aetiology, it has also been sug-
gested that ongoing alcohol consumption associated
with end-stage alcoholic liver disease may have addi-
tional detrimental eﬀects on the hypothalamic–pitui-
tary–gonadal axis in men and women [25].
From a functional perspective, cirrhosis in men has
been reported to be associated with decreased volume
of ejaculatory ﬂuid [27], and reduced libido/interest in
sex [27,29]. Erectile dysfunction including frank impo-
tence, has been reported to some degree in anywhere
from 60% to 90% of patients with cirrhosis [27,29]. In
women, one survey documented close to 60% of patients
with chronic liver disease pre-transplant suﬀering men-
strual irregularities: half of this group had amenorrhea
compared to less than 20% of women classiﬁed as
ALF pre-transplant experiencing menstrual problems
[30]. Of some interest is a recent report that found
60% of women on a transplant waiting list suﬀered
amenorrhea compared to 19% with cholestatic liver dis-
ease (p = 0.0009) [31]. One of the diﬃculties in interpret-
ing studies that report sexual function in patients with
cirrhosis is that the severity of the end-stage disease
may be either unclear or simply not stated. Although
it would appear intuitive that patients with more severe
cirrhotic decompensation would suﬀer worse sexual dys-
function, until recently, this has not been deﬁnitively
correlated with any index of liver function. In an impor-
tant paper, using MELD scores as an indicator of liver
disease severity, Sorrell and Brown, from the University
of Nebraska, correlated sexual activity pre-transplant
with MELD scores [29] They found that patients with
no reported sexual activity had the highest mean MELD
scores of 15.18, whereas those patients that reported no
change in sexual activity had the lowest MELD scores of
10.74. Those who were in-between the highest and low-est MELD scores (=13.88) also reported decreased sex-
ual activity. These investigators also found a similar
correlation between MELD score and erectile dysfunc-
tion [32], thereby scientiﬁcally and deﬁnitively conﬁrm-
ing what clinicians have long-suspected.
3.3. Sexual health after liver transplantation
Physiologically, the marked hypothalamic–pituitary–
gonadal abnormalities of end-stage liver disease are
reversed post-transplantation [24,25,27] although it has
been suggested that some transplant recipients may have
persisting abnormalities [27]. Functionally, the vast
majority of women of child-bearing age will recover reg-
ular menstrual bleeding within one year post-transplant
[30,31] and a signiﬁcant proportion will experience men-
ses within the ﬁrst month [30,33]. Sexual health, which
encompasses sexual function and satisfaction, however,
is inﬂuenced by more than just hormonal and endocri-
nologic physiology. Concomitant health issues, medica-
tions, aging, as well as psychological and social issues
may also aﬀect post-transplant sexual health. The
post-transplant literature on sexual health is mixed,
reﬂecting the context of the study, the study popula-
tion(s) and the speciﬁc questions asked. Post-transplant
quality of life studies using standard but generic instru-
ments tend to report improvements in sexual function as
summarized in an excellent meta-analysis by Bravata
and colleagues [4]. A large Spanish study however,
reported that older recipients, women, and those who
were unemployed long-term pre-transplant demon-
strated worse adjustment in the sexual domains of a psy-
chosocial adjustment scale [5].
Generic quality of life and psychosocial instruments,
however, do not study speciﬁc issues concerning sexual-
ity post-transplantation. In terms of speciﬁc questions
regarding sexual activity, a Brazilian study [33] of rela-
tively young post-transplant women (mean age 44 years)
found that 75% reported weekly sexual intercourse with
70% experiencing orgasm and 70% experiencing satisfac-
tion with their sexual health. The North American expe-
rience, however, is markedly less favourable. A survey of
post-liver transplant recipients in British Columbia,
Canada [34], reported that 32% of 150 respondents
(median age = 54 years, 93% were a minimum of one-
year post-transplant) experienced de novo post-trans-
plant sexual dysfunction (i.e. the recipients felt that the
problems began after liver transplantation). Twenty-
three percent and 26% of men and women, respectively,
reported decreased libido and 33% of men and 26% of
women reported diﬃculty with orgasm [34]. Thirty per-
cent of men in the same study reported some degree of
erectile dysfunction and 40% of females reported
dysparenuia only after their liver transplant. Not sur-
prisingly, 36% blamed their sexual dysfunction on their
immunosuppressive medications (approximately 60%
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approximately 60% reported that, despite their prob-
lems, they were ‘‘moderately” to ‘‘very satisﬁed” with
their sexual relationships suggesting that sexual func-
tion/performance itself is only a component of overall
post-transplant sexual health. A recent American study
of 39 post-transplant recipients surveyed by a telephone
interviewer was less favourable than our own reported
Canadian experience [29]. Overall, 44% reported a
decreased satisfaction with sex, and only 24% of men
reported ‘‘no problems” with erectile dysfunction,
although 35% did report an increased ‘‘interest in sex”
and 28% reported an increased frequency of intercourse.
If sexual dysfunction exists in a signiﬁcant minority
of post-transplant patients, can anything be done about
it? Over a decade ago, it was reported that close to 70%
of solid organ transplant recipients did not receive any
form of education or counseling on the matter [35]
and in liver transplantation, it is uncertain if this has
changed signiﬁcantly. Clearly referral and communica-
tion to those with expertise in the area would be appro-
priate if the transplant clinics did not feel comfortable
with this area of healthcare. In terms of pharmacologic
therapy for erectile dysfunction, our own study [34] dis-
covered that, unknown to the transplant team, 19% of
transplant respondents were using the phosphodiester-
ase-5 inhibitor sildenaﬁl (Viagra; Pﬁzer Canada Inc.,
Kirkland, Que., Canada). Sildenaﬁl or tadalaﬁl (Eli
Lilly, Indianapolis, USA) another longacting phospho-
diesterase-5 inhibitor use have not been previously
reported in the liver transplant setting, although its suc-
cessful use has been reported in post-renal transplant
recipients with erectile dysfunction [36–38]. Neither
adverse eﬀects nor interactions with cyclosporine or
tacrolimus have been found in renal transplant clinics,
although the elimination of sildenaﬁl was prolonged
[38]. In our liver transplant clinic, 65% of sildenaﬁl users
reported that they felt that the drug was beneﬁcial, sug-
gesting that sildenaﬁl use post-transplant should be fur-
ther studied.4. Contraception after liver transplantation: how and
when? (Beat Mullhaupt)
As discussed in the previous section, women with
end-stage liver disease are often amenorrheic and have
a signiﬁcantly reduced fertility [33]. In parallel with an
improvement in general well being, menstrual cycles will
return in most women (>90%) of reproductive age
within the ﬁrst year after transplantation [33,39]
Together with menstruation, sexual function can return
to normal and consequently women who have under-
gone successful OLT may conceive as early as one
month following OLT [40] Although there is a clear
need for contraception in fertile women after OLT, onlya few studies have investigated the diﬀerent contracep-
tive possibilities in this special population. The data
on which to base these recommendations are therefore
very limited and consequently opinion is derived largely
from kidney transplant populations.
As such, the same contraceptive methods are avail-
able for women after liver transplantation as for the gen-
eral population. However OLT recipients have some
factors, which deserve special attention. These include
an increased risk of infection and (some) cancer(s),
increased prevalence of chronic renal insuﬃciency and
systemic hypertension, increased cardiovascular risk,
and greater potential for hepatotoxicity and drug inter-
actions by virtue of lifelong requirement for immuno-
suppressive therapy. The available contraceptive
methods will be reviewed in turn.
4.1. Interrupted intercourse and barrier methods
Periodic abstinence and coitus interruptus are ineﬀec-
tive methods of contraception, but are not associated
with side eﬀects or drug interactions. Among 16 unin-
tended/unplanned pregnancies in female kidney trans-
plant recipients from Iran, 94% of patients used coitus
interruptus as their only form of contraception [41].
Therefore, this method can not be recommended. Nev-
ertheless, one quarter of US female kidney transplant
recipients that participated in a survey on contraceptive
practices reported using no contraception at all [42].
Barrier methods, such as diaphragms and condoms
are widely used in the general population, are of low
cost and drug interactions are avoided. However, the
use of diaphragms increases the risk of urinary tract
infections by a factor of two compared to women on
oral contraceptives. This increased risk of infection
can be especially problematic in the transplant popula-
tion [43]. Regarding the use of condoms, these represent
the only form of contraception that prevents transmis-
sion of (most) sexually transmitted disease(s), and
should therefore be recommended for all patients with-
out a stable sexual partner [44]. Most barrier methods
should be combined with a spermicide to increase their
eﬃcacy. However, failure rates are reported to range
between 15% and 32% [45]. Nevertheless, all barrier
methods can be recommended for birth control in
female transplant recipients [44].
4.2. Intrauterine contraceptive devices (IUD)
Two types of intrauterine devices are currently avail-
able: The copper containing ParaGard and levonorge-
strel-releasing Mirena coil [45]. Both are very eﬀective
at preventing unplanned/unintended conception with
failure rates reported below 1% during the ﬁrst-year of
use, and they are eﬀective over a period of 5 (Mirena)
to 10 years (ParaGard). Two factors, which limit the
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infectious complications upon insertion of a foreign
body into the uterine cavity [46], and a reduced eﬀective-
ness in immunosuppressed patients [47]. The fear of
infectious complications however, appear to be more
theoretical than real. To date, there are no studies in
cohorts of transplant patients that can conﬁrm or refute
this increased risk [46]. However, in a prospective cohort
of 156 HIV-positive women, no increased rate of infec-
tious complications was observed when compared to
493 HIV-negative women [48].
Based on such data, IUDs are classiﬁed as category
two contraceptive devices for HIV-positive women
receiving antiviral therapy. This indicates that the bene-
ﬁt exceeds the risk associated with use of IUDs [45]. The
reduced eﬀectiveness of IUD among transplant patients
is based on failures in two kidney transplant patients
and on the theoretical basis that immunosuppression
reduces the local inﬂammatory response [47]. It is gener-
ally believed that the eﬀectiveness of an IUD depends on
local inﬂammatory processes. Macrophages are presum-
ably the most important inﬂammatory cells responsible
for the action of IUDs [49]. Most immunosuppressive
drugs however, inhibit T cell activation and their eﬀect
on macrophages is limited. On the other hand, drug
interactions are obviously only of minor importance,
and therefore it has recently been suggested that IUDs
maybe the ‘perfect’ option for transplant recipients [44].
4.3. Hormonal contraception
A number of hormonal contraceptives administered
in various ways are currently available to OLT recipi-
ents with a one-year failure rate that varies between
3% and 8% [45].
4.3.1. Combined oral or transdermal contraceptives
Combined oral contraceptives (COCs) are the most
commonly used type of contraceptive prescribed in
many parts of the world. In patients who have under-
gone solid organ transplantation the same contraindica-
tions as in the general population have to be respected,
such as a personal history of myocardial infarction,
stroke or deep vein thrombosis, smokers over the age
of 35 (>15 cigarettes/day), migraine with focal aura,
uncontrolled systemic hypertension, marked unex-
plained liver test abnormalities and hepatic adenoma
[45]. In addition, since COCs are metabolized by the
hepatic cytochrome P4503A4 system, drug interactions
are of at least theoretical concern.
The concentrations of cyclosporine and tacrolimus,
which are both also metabolized by the cytochrome
P4503A4 could be increased by the concurrent adminis-
tration of COCs. However, in clinical practice these inter-
actions aremost likely ofminor importance. Surprisingly,
only few published data are available that have analysedthe eﬃcacy and safety in female liver transplant recipients.
In one study of 15 female liver graft recipients, who used
hormonal contraceptives after transplantation for at least
12months, the authors could show, that COCswere eﬀec-
tive, well tolerated and had no impact on graft function
[50]. FinallyCOCsmight increase the risk for cervical can-
cer, whilst at the same time reduce the risk for endometrial
and ovarian cancer [46].
Therefore, COCs should be considered carefully after
liver transplantation. It has recently been recommended
that COCs should only be used in recipients with stable
graft function for at least 6–8 months and without other
contraindications to commencing therapy [51]. In addi-
tion, careful monitoring of liver enzymes should be per-
formed. Far less experience is available for both the
transdermal contraceptive patch and the vaginal ring,
although one potential advantage of the vaginal ring
relates to the absence of the ﬁrst pass metabolism in
the liver.
4.3.2. Progesterone only contraceptives
An alternative, especially for women with contraindi-
cations to estrogens, is the progestin-only method of
contraception. These agents can be delivered orally, as
an intramuscular injection or as an implantable device.
Progestins have a minimal eﬀect on the liver and drug
interactions are less common. Depot medroxyprogester-
one acetate (DMPA) is a synthetic progestin, which is
delivered as an injection every three months. It is highly
eﬀective with a failure rate of around 2% [45] Its side
eﬀect proﬁle is associated with irregular menstrual
bleeding, weight gain and decreased bone mineral den-
sity. These latter two issues are especially important in
OLT populations, whereby patients have to deal with
weight gain post-transplant in addition to the high like-
lihood of pre-existing osteoporosis in the context of cir-
rhosis and end-stage chronic liver disease. An
etonorgestrel implant, which is implanted in the subcu-
taneous tissue, is an alternative to DMPA. It can pro-
vide protection for up to three years. Its side eﬀect
proﬁle is similar to DMPA other than for the risk of
reduced bone mineral density which is signiﬁcantly less.
4.4. Surgical sterilization
In studies of adult renal and liver transplant recipi-
ents 60% and 24%, respectively, choose surgical steriliza-
tion as the contraceptive method of choice [39,52].
Surgical sterilization is very eﬀective at preventing
unwanted conception, and drug interactions can be
avoided. Despite its eﬃcacy, this method may not be a
viable option for women who might wish to consider a
pregnancy at a future time-point.
In summary, female patients after OLT need an eﬀec-
tive, safe and reversible contraceptive method to avoid
unwanted pregnancy. Table 2 summarizes the eﬃcacy
Table 2
Contraceptive methods available after liver transplantation
Eﬀectiveness Drug interactions Reversibility
IUD ++ – ++
COC ++ + ++
Progestin-only pill ++ () ++
DMPA ++ () ++
Barrier method +  ++
Surgical sterilisation ++ – –
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IUDs appear to be the method of choice. However, this
is based on consensus opinion extrapolated predomi-
nantly from the non-transplant literature rather than
ﬁrm data derived from transplant patients [44].5. What do we know about pregnancy after liver
transplantation? (Michael A. Heneghan)
Although the majority of OLT recipients are men or
women of non-child-bearing age, as discussed previously,
a signiﬁcant proportion of recipients are pre-menopausal
women and many of them are of child-bearing potential
[53]. OLT reverses the biochemical imbalances associated
with pre-transplant infertility [54–57]. The ﬁrst successful
pregnancy following OLT occurred in 1978 and led to an
excellent foetal outcome despite low birth weight [58].
Whilst subsequent decades have seen an expansion in
our knowledge of pregnancy in the OLT recipient, much
uncertainty remains regarding the absolute rate of con-
ception amongst liver graft recipients and the success of
subsequent pregnancies. Thus, the major questions
regarding pregnancy post-transplantation are:
(1) What is the eﬀect of immunosuppression on foetal
development and outcomes ?
(2) How does OLT aﬀect the foetal and maternal out-
comes of pregnancy?
(3) What is the eﬀect of pregnancy on the allograft?5.1. Eﬀect of immunosuppression on foetal outcomes
5.1.1. In-utero eﬀects of immunosuppression
An increased risk of teratogenicity has been a con-
cern regarding the use of immunosuppressive drugTable 3
United States of America Food and Drug Administration categories of the saf
Categories of drug safety in pregnancy
(A) Controlled studies show no risk: adequate, well-controlled studies in pre
(B) No evidence of risk in humans: either animal ﬁndings show risk (but hum
animal ﬁndings are negative
(C) Risk cannot be ruled out: human studies are lacking and animal studies
beneﬁts may justify the potential risk
(D) Positive evidence of risk: investigational or post-marketing data show ri
(X) Contraindicated in pregnancy: studies in animals or humans, or investig
outweighs any possible beneﬁt to the patienttherapy during pregnancy. However, the absolute risk
of teratogenicity and foetal loss with the commonly
used immunosuppressive agents following OLT,
appears low. Evidence has largely been gathered from
experimental studies in animals or relatively small
case series. Subsequently, such data have signiﬁcant
limitations in its ability to accurately predict out-
comes. The most commonly used immunosuppressive
drugs used post-OLT, in both Europe and the USA,
are cyclosporine A (CyA), tacrolimus and predniso-
lone. The United States Food and Drug Administra-
tion (FDA) categorise the safety of drugs in
pregnancy based on available evidence. These are pre-
sented in Table 3. In the early years of OLT, CyA
was the mainstay of immunosuppressive therapy, in
conjunction with prednisolone and/or azathioprine.
5.1.2. Cyclosporine A and azathioprine
Although controversy surrounds the trans-placental
transfer of CyA, with some reports ﬁnding no signiﬁcant
placental levels and others demonstrating levels equiva-
lent to those observed in maternal blood [58,59], its ter-
atogenic potential appears to be low. Premature labour,
low birth weight as well as transient neonatal hyperkal-
aemia and elevated serum creatinine concentrations
have, however, been reported [60–63].
A meta-analysis of 15 studies of women who received
CyA during pregnancy reported major malformations in
4.1% of live births, a rate not signiﬁcantly higher than
that noted in the general population [61]. A single center
study of 154 pregnancy outcomes in 115 renal transplant
recipients compared the eﬀects of CyA immunosuppres-
sion with azathioprine and prednisone [64]. The CyA
group had a lower rate of complications with no congen-
ital malformations being noted, although CyA treated
patients were more likely to have diabetes and systemic
hypertension, and the child was more likely to have a
low birth weight. CyA is considered a class C drug in
terms of its risk for pregnancy by the United States
Food and Drug Administration (FDA).
Azathioprine as an immunosuppressant has classi-
cally been prescribed in conjunction with CyA in trans-
plant recipients and in the ﬁrst two decades of solid
organ transplant signiﬁcant experience was obtained
with the drug [39,61]. In general, azathioprine is consid-ety of drugs in pregnancy
gnant women have failed to demonstrate risk to the foetus
an ﬁndings do not) or, if no adequate human studies have been done,
are either positive for foetal risk or lacking as well. However, potential
sk to foetus. Nevertheless, potential beneﬁts may outweigh the risk
ational or post-marketing reports have shown foetal risk which clearly
514 M.A. Heneghan et al. / Journal of Hepatology 49 (2008) 507–519ered relatively safe during pregnancy in both non-trans-
plant and transplant populations [39,61,64], although, it
is considered a class D drug by the FDA as a conse-
quence of reports of congenital malformation in some
exposed infants.
5.1.3. Tacrolimus
In the last decade, tacrolimus has supplanted CyA as
the mainstay of immunosuppression post-OLT. Data on
its safety in pregnancy are emerging. Among 100 preg-
nancies in 84 women treated with tacrolimus, 68 preg-
nancies progressed to live birth and 60% of these live
births were premature [65]. The neonatal malformation
rate was 4%, similar to the rate associated with CyA
[61]. These outcomes have been similar across a range
of reports [66–69]. In common with CyA, tacrolimus is
considered a class C drug in terms of its risk in preg-
nancy by the FDA.
5.1.4. Corticosteroids
Whilst both prednisone and prednisolone cross the
placenta, only small quantities appear in foetal cord
blood [70]. Evidence suggests that the major foetal risks
regarding steroids are cleft palate (particularly with high
dose exposure in the ﬁrst trimester), premature rupture
of the membranes and intrauterine growth retardation
[71,72]. A systematic review of studies of women who
took corticosteroids during pregnancy for non-trans-
plant-related conditions, demonstrated a 3.4-fold
increased risk of cleft palate [73]. Meanwhile, the
increased risk of low birth weight in these studies is fre-
quently confounded by the severity of underlying disease
necessitating corticosteroid therapy. Foetal adrenal
hypoplasia and suppression of the foetal pituitary gland
have also been described though both of these are
uncommon due to the rapid maternal metabolism, bind-
ing to plasma proteins and placental breakdown of cor-
ticosteroids. Prednisone is considered a class B drug in
terms of its risk for pregnancy by the FDA.
5.1.5. Mycophenolate mofetil and sirolimus
These two novel immunosuppressants have gained
increased popularity either as add-on immunosuppres-
sion de novo following OLT as an alternative to azathi-
oprine, or alternatively as steroid sparing agents.
Mycophenolate mofetil (MMF), an inhibitor of purine
biosynthesis, and sirolimus, an inhibitor of the mamma-
lian target of rapamycin (MTOR), have been shown to
cause abnormal ova development, and therefore, are
both potentially teratogenic [74]. In a large report of reg-
istry data from all solid organ recipients, 18 kidney
recipients reported 26 pregnancies with exposure to
MMF. Of these, there were 15 live births, and 11 spon-
taneous abortions. Structural malformations were
reported in four of the 15 children (26.7%) including
hypoplastic nails and shortened ﬁfth ﬁngers, microtiawith cleft lip and palate, microtia alone, and neonatal
death with multiple malformations in one case [74].
One kidney/pancreas recipient reported one spontane-
ous abortion whereas, three liver recipients reported
three pregnancies; two live births without malforma-
tions, and one second trimester spontaneous abortion.
Two heart recipients reported one live birth without
malformations and two spontaneous abortions. In
another series, data from 119 human pregnancies with
maternal exposure to MMF found outcome data for
65 and demonstrated a live birth rate of only 34% with
miscarriage occurring in 31% and elective abortion in
20% [62]. The rate of congenital abnormalities, at 15%,
was higher than that seen in the general United States
population [75].
Sirolimus exposures during pregnancy was reported
in seven recipients (four kidney, one kidney/pancreas
and two liver) reporting four live births (one infant
whose mother was switched from MMF to SRL during
late pregnancy had cleft lip and palate and microtia) and
three spontaneous abortions [74]. MMF is considered
therefore by the FDA a class D drug in terms of the risks
associated with its use in pregnancy, whereas, sirolimus
has been designated as class C, albeit, with less data
available to assess outcomes during pregnancy.
5.1.6. Other immunosuppressive agents
Other immunosuppressive agents which pregnant
OLT recipients may be exposed to include the monoclo-
nal antibody muromonab and anti-thymocyte globulin
(ATG). To date, no human studies regarding their safety
in pregnancy exist. Consequently, all three are categor-
ised as class C drugs in term of pregnancy risk by the
FDA.
5.2. Breast feeding
Most transplant physicians advise against breastfeed-
ing due to concerns over the safety of neonatal exposure
to immunosuppressants, with the optimal level above
which complications occur being unknown. Corticoste-
roids, CyA and tacrolimus are all known to be excreted
in breast milk whilst no data exist for sirolimus, muromo-
nab or ATG. Corticosteroids, however, are excreted in
extremely low concentrations andare felt to be safe during
breastfeeding [76]. Meanwhile, both CyA and tacrolimus
levels are excreted in breast milk and in some cases levels
are equivalent to, or even exceed, that of maternal plasma
and are therefore contraindicated [77–79].
In a seminal study from Jain et al., 15 pregnancies
post-OLT were described under tacrolimus immunosup-
pression and all were followed prospectively. Maternal,
cord and neonatal blood, as well as placental tissue was
stored at, or shortly after, delivery for determination of
tacrolimus levels. Mean tacrolimus concentrations were
4.3 ng/mL in placenta versus 1.5, 0.7, and 0.5 in mater-
M.A. Heneghan et al. / Journal of Hepatology 49 (2008) 507–519 515nal, cord, and neonate plasma, and 0.6 in the initial
breast milk, respectively [79]. These neonates, however
were not subsequently breastfed and, as a consequence,
little data have been accumulated on the safety or other-
wise of neonatal exposure to the commonly used agents
post-transplantation. What evidence exists is limited to
small numbers collated by a national registry or in
patients who have ignored physician advice not to
breastfeed [67]. Such series have not demonstrated obvi-
ous concerns but are extremely limited by their size.
5.3. Foetal and maternal outcomes following liver
transplantation
Conception in the post-liver transplant recipient,
although commonly resulting in live birth, does not
always guarantee a successful outcome. The commonest
encountered foetal problems are foetal loss, prematurity
(deﬁned as birth occurring prior to 37 weeks gestation)
and low birth weight (<2500 g), while maternal risks
include systemic hypertension/pre-eclampsia, gesta-
tional diabetes, graft dysfunction and, in rare instances,
maternal death. Therefore, it is preferable that post-
transplant patients who conceive, are managed by cen-
ters who have easy access to the transplant team and
multi-disciplinary care teams available to deal with the
obstetric complications that arise.
5.3.1. Outcome studies of pregnancy post-liver
transplantation
National registries have been established to record
foetal and maternal outcomes following any organ
transplantation. The most comprehensive registry is
the National Transplantation Pregnancy Registry
(NTPR) maintained at Philadelphia in the United
States. In 2004 the NTPR reported data regarding preg-
nancy following liver transplantation in 189 patients
(these results are summarized in Table 4) [67]. Experi-
ence from our own center, has led to the report of the
largest individual series of pregnancies in OLT recipients
and demonstrated a live birth rate of 50/71 (70%) [68].
Although rejection episodes were noted in 17%, no
patient lost their graft as a consequence of pregnancy
and no maternal deaths were noted in this series. TheseTable 4
National Transplantation Pregnancy Registry (NTPR) Report 2004: foetal an
Foetal outcomes
Live births 73%
Spontaneous abortion 19%
Therapeutic abortion 6%
Premature birth 30%
Low birth weight 30%
Stillbirth 2%
Neonatal deaths 0%
Mean gestation 37 weeksdata mirror UK registry data which are, to date, incom-
plete [80].
Available evidence therefore suggests that there is an
increased incidence of complications, including preterm
delivery, foetal growth retardation, systemic hyperten-
sion/pre-eclampsia (PET), and gestational diabetes in
pregnancy post-OLT. [66–68,80–84]. Foetal and mater-
nal complications reported in published, single center
series are summarized in Table 5.
5.3.2. Low birth weight
The prevalence of low birth weight is considerably
higher than in the general population where, in the Uni-
ted Kingdom it is reported to occur in 5% [85]. Whilst
the risk of preterm birth may be related to episodes of
graft rejection and early onset pre-eclampsia [75], this
has not been conclusively demonstrated.
5.3.3. Pregnancy loss
Nagy et al. [75] reported that the interval between
transplantation and conception was shorter in those
who suﬀered abortions or miscarriages (mean
24.4 ± 24.3 months versus 47.8 ± 28.7 months
p = 0.02). They therefore suggested conception be
delayed for up to two years post-OLT. Contrary to this
recommendation, experience at our institution has not
shown a signiﬁcant association between conception in
the ﬁrst year post-OLT and increased foetal and mater-
nal complications [78].
5.3.4. Maternal risks
The most common maternal risks are systemic hyper-
tension and/or pre-eclampsia, both of which occur at far
higher frequency than in the general population. The
cause of these complications is multi-factorial, but
potential factors include the vasoconstrictive eﬀects of
calcineurin inhibitor therapy, chronic corticosteroid
use and underlying renal dysfunction. These issues are
not unique to OLT, with similar rates observed in renal
transplant populations [82,83]. Moreover, the risk of
systemic hypertension, renal dysfunction and pre-
eclampsia in pregnant patients treated with tacrolimus
therapy appears to be lower than that seen with CyA
[67,79,81,84].d maternal outcomes in liver transplant recipients
Maternal outcomes
Hypertension in pregnancy 35%
Pre-eclampsia 23%
Gestational diabetes 5%
Infection 27%
Caesarean section rate 35%
Graft rejection 8%
Graft loss within 2 years 7%
Mean OLT-conception 4.3 years
Table 5
Summary of important foetal and maternal outcomes of pregnancy in liver transplant recipients in single center series
Author [Reference] Live birth
rate (%)
Pre-term (%) Mean birth
weight (g)
HTN/PET
(%)
Graft
dysfunction (%)
CS rate
(%)
Christopher et al., 2006 n = 71 [68] 70 na 2668 20/13 17 40
Nagy et al., 2003 n = 38 [75] 63 29 2762 21/8 17 46
Jain et al., 2003 n = 49 [79] na 49 2797 11/2 25^ 47
Rayes et al., 1998 n = 19 [82] 32 8 2659 44/0 11 54
Wu et al., 1998 n = 22 [83] na 14 2876 14/14 5 32
Ville et al., 1993 n = 19 [81] 32 0 2990 na/27 5 45
Scantlebury et al., 1990 n = 20 [69] 80 55 2940 30/20 30* 63
Key: ^not biopsy proven; * all abnormal LFTs; na, not available.
Abbreviations: HTN, hypertension; PET, pre-eclamptic toxaemia.
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The rate of caesarean section (CS) is considerably
higher in patients post-OLT, with individual series quot-
ing rates of 35–63% [66,67,75,78,79], in comparison to
the general population rate of 23% recently reported
from the UK [85]. Many authors report that the major-
ity of CS are performed for standard obstetric indica-
tions and it is likely that prematurity and low birth
weight predispose to foetal distress during childbirth
thereby necessitating CS [66,75].
The rate of CS is, however, variable and may relate to
diﬀering experience in OLT and subsequent experience
in managing pregnancy post-OLT. A learning curve
may therefore exist as evidenced by a reduction of CS
rates series over time in one series [68].
5.4. Eﬀect of pregnancy on allograft function
Biopsy proven graft dysfunction in the form of acute
cellular rejection occurs in approximately 10–20% of
pregnant OLT recipients, but graft losses are rare
[67,68,75]. Graft dysfunction, when present, generally
responds either to augmentation of the baseline immu-
nosuppression or may require additional therapy in
the form of intravenous methylprednisolone or even
ATG. Graft dysfunction is, however, associated with
increased rates of miscarriage and lower birth weights.
There is no evidence to date that it leads to increased
maternal mortality [67,75]. Available evidence suggests
that, overall, episodes of rejection do not occur with
any greater frequency than in non-pregnant individuals
and that liver biopsy is safe in pregnancy [68,75].
Regarding the timing of conception, most transplant
centers advise that conception be delayed for at least 12
months after transplantation and this is supported by
the NTPR [67]; although, some authors advocate wait-
ing 24 months [75,81]. This delay is to allow for stability
of both graft function and immunosuppressive therapy,
including possible withdrawal of corticosteroids. More-
over, opportunistic infections are less likely to occur
after this period.
A further key issue for practitioners is that of whether
immunosuppression should be reduced either prior to orduring pregnancy. Our own experience having applied
both strategies at diﬀerent time-points over a 20 year
period, is to maintain standard levels of immunosup-
pression during pregnancy appropriate for the time
course, post-transplant [68]. This approach limits
graft-related issues, whilst allowing the multi-disciplin-
ary team to deal appropriately with the known compli-
cations associated with pregnancy.6. Summary
In this the 11th Forum, we have reviewed many of the
issues pertaining to sexuality and sexual function in the
liver transplant recipient. It is disappointing that despite
forty years of OLT, only a relatively small literature
exists in relation to many of these topics, particularly
the area of sexual health.
As hepatologists and transplant physicians, much is
made of graft and patient survival and indeed it is cor-
rect to do so. However, it is clear that our patients
wish to, and do form and maintain normal healthy sex-
ual relationships. Yet, this area of transplantation has
been largely neglected not just in OLT, but also across
other organs. Indeed, despite the many successful preg-
nancies that do occur in our transplant recipients, the
management of such patients has been derived from
largely self-reported patient series, and the criticism
of all such series is that there exists a reporting bias
of predominantly successful outcomes. That said, the
multi-disciplinary transplant team should not fear
addressing issues of sexuality and sexual health, but
rather encourage it. Indeed, all concerned, both
patients and healthcare providers alike may be pleas-
antly surprised by the responses and the interest in
the topic!
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